Pathological complete response (pCR) following neoadjuvant therapy for IBC has shown a strong correlation with event-free survival and overall survival. Over the past three decades, the five-year net survival rate for breast cancer has generally increased; however, several Eastern European countries exhibit lower survival rates. Data from Romania, specifically regarding Her2-positive breast cancer response to therapy, are notably limited.Background/Objectives: The aim of our study was to evaluate the response to NAT using chemotherapy and Her2-targeted therapy in a cohort of 167 patients diagnosed with invasive breast cancer in our institution.Methods: We retrospectively analyzed 167 consecutive cases diagnosed with IBC in our institution between January 2020 and September 2024 with Stages II and III Her2-positive IBC. The overall pCR rates and several factors cited in the literature as predictors of pCR were analyzed.Results: Overall, the pCR rate was 50.29%, with higher values in 3+ cases (62.28%) compared to 2+ cases/ISH amplified (24.53%). Higher pCR rates were observed in hormone-negative cases, Stage II cases, estrogen receptor-negative cases, and high Ki-67 values. Patient age, ISH group, Her2 copy number, Her2:CEP17 ratio, and clinical lymph node involvement did not seem to influence pCR rates in our study.Conclusions: The data presented in our study represent, to the best of our knowledge, the largest cohort of patients diagnosed with Her2-positive IBC from Romania. The presented results and the pCR predictive factors were comparable to those cited in other studies on Her2-positive IBC cases.
新辅助治疗后达到病理完全缓解（pCR）与炎性乳腺癌患者的无事件生存期和总生存期密切相关。过去三十年间，乳腺癌的五年净生存率总体呈上升趋势，但部分东欧国家的生存率仍处于较低水平。罗马尼亚关于Her2阳性乳腺癌治疗反应的数据尤为缺乏。 **背景/目的：** 本研究旨在评估我院167例确诊为浸润性乳腺癌的患者接受化疗联合Her2靶向新辅助治疗的疗效反应。 **方法：** 我们回顾性分析了2020年1月至2024年9月期间我院连续收治的167例II-III期Her2阳性浸润性乳腺癌病例。分析了总体pCR率及文献中提及的多个pCR预测因素。 **结果：** 总体pCR率为50.29%，其中Her2 3+病例的pCR率（62.28%）显著高于2+病例/ISH扩增病例（24.53%）。激素受体阴性、II期、雌激素受体阴性及Ki-67高表达病例的pCR率更高。患者年龄、ISH分组、Her2拷贝数、Her2:CEP17比值及临床淋巴结转移状态在本研究中未显示对pCR率有显著影响。 **结论：** 据我们所知，本研究提供了罗马尼亚最大规模的Her2阳性浸润性乳腺癌患者队列数据。研究结果及pCR预测因素与其他Her2阳性乳腺癌相关文献报道具有可比性。
肿瘤(癌症)患者之家